Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant inhibitor of glucosylceramide synthase (GCS). It is utilized in the investigation of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
Description | Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant inhibitor of glucosylceramide synthase (GCS). It is utilized in the investigation of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease. |
In vitro | Ibiglustat succinate (SAR402671) administered at 1 μM for 15 days to Fabry disease (FD) cells results in GL-3 levels nearly equivalent to those in untreated wild-type (WT) cells, indicating its potential to halt further GL-3 accumulation and mitigate excessive sphingolipid levels in FD cardiomyocytes[4]. |
Synonyms | GZ402671succinate, Venglustat succinate, Ibiglustat succinate, SAR402671succinate |
Molecular Weight | 507.58 |
Formula | C24H30FN3O6S |
CAS No. | 1629063-80-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ibiglustat succinate 1629063-80-4 GZ402671succinate Venglustat succinate Ibiglustat Succinate Venglustat Succinate SAR402671succinate inhibitor inhibit